Ann Schalenbourg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ann Schalenbourg has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Alexandre Moulin
Jules-Gonin Eye Hospital, Department of Ophthalmology, University of Lausanne, FAA, Switzerland
4 shared publicationsLeonidas Zografos
Jules-Gonin Eye Hospital, Department of Ophthalmology, University of Lausanne, FAA, Switzerland
4 shared publications- Leonidas Zografos
Hôpital Ophtalmique Jules-Gonin
4 shared publications - Leonidas Zografos
University of Lausanne
3 shared publications - Alessia Pica
Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, 5232 Villigen, Switzerland
2 shared publications Luis Schiappacasse
Department of Oncology, Radiation Oncology Service, CHUV, University of Lausanne, Lausanne, Switzerland
2 shared publications
Latest Publications
- 3 May 2025
- Published by Springer Nature
- p. 77-85
Uveal Melanoma: Clinical Features
- Open Access
Clinical Outcomes in AYAs (Adolescents and Young Adults) Treated with Proton Therapy for Uveal Melanoma: A Comparative Matching Study with Elder Adults
Objective: The aim of this study was to compare the clinical outcomes of adolescents and young adults (AYAs) with those of elder adult patients treated with proton therapy (PT) for uveal melanoma (UM). Material and Methods: A retrospective, comparative study was conducted in UM patients who underwent PT at the Ocular Oncology Unit of the Jules-Gonin Eye Hospital (University of Lausanne, Lausanne, Switzerland) and the Paul Scherrer Institute (PSI); (Villigen, Switzerland) between January 1997 and December 2007. Propensity score matching (PSM) was used to select for each AYA (between 15–39 years old) an elder adult patient (≥40 years) with similar characteristics. We assessed ocular follow-up, local tumor control, metastasis incidence, and overall and relative survival (OS and RS). Non-terminal outcomes were then compared between the two groups using competing risk survival analysis. Results: Out of a total of 2261 consecutive UM patients, after excluding 4 children (p = 0.005), while the elder patients were more likely to have other neoplastic diseases at presentation (9% vs. 3.7%; p = 0.004). Ocular outcomes and local tumor control were similar in both groups. Cumulative metastasis incidence for the AYA and elder adult groups was 13% and 7.9% at 5 years and 19.7% and 12.7% at 10 years, respectively, which was not significantly different between the groups (p = 0.214). The OS was similar in the two groups (p = 0.602), with estimates in the AYA and elder adult groups of 95.5% and 96.6% at 5 years and 94.6% and 91.4% at 10 years, respectively. However, the relative survival (RS) estimation was worse in the AYA group than the elder group (p = 0.036). Conclusion: While AYAs treated with PT for UM have similar ocular outcomes and present the same metastasis incidence and OS as elder adults, their RS is worse than that in elder adults, when compared with the population in general.
Open AccessClinical Outcomes in AYAs (Adolescents and Young Adults) Treated with Proton Therapy for Uveal Melanoma: A Comparative Matching Study with Elder Adults
Objective: The aim of this study was to compare the clinical outcomes of adolescents and young adults (AYAs) with those of elder adult patients treated with proton therapy (PT) for uveal melanoma (UM). Material and Methods: A retrospective, comparative study was conducted in UM patients who underwent PT at the Ocular Oncology Unit of the Jules-Gonin Eye Hospital (University of Lausanne, Lausanne, Switzerland) and the Paul Scherrer Institute (PSI); (Villigen, Switzerland) between January 1997 and December 2007. Propensity score matching (PSM) was used to select for each AYA (between 15–39 years old) an elder adult patient (≥40 years) with similar characteristics. We assessed ocular follow-up, local tumor control, metastasis incidence, and overall and relative survival (OS and RS). Non-terminal outcomes were then compared between the two groups using competing risk survival analysis. Results: Out of a total of 2261 consecutive UM patients, after excluding 4 children (p = 0.005), while the elder patients were more likely to have other neoplastic diseases at presentation (9% vs. 3.7%; p = 0.004). Ocular outcomes and local tumor control were similar in both groups. Cumulative metastasis incidence for the AYA and elder adult groups was 13% and 7.9% at 5 years and 19.7% and 12.7% at 10 years, respectively, which was not significantly different between the groups (p = 0.214). The OS was similar in the two groups (p = 0.602), with estimates in the AYA and elder adult groups of 95.5% and 96.6% at 5 years and 94.6% and 91.4% at 10 years, respectively. However, the relative survival (RS) estimation was worse in the AYA group than the elder group (p = 0.036). Conclusion: While AYAs treated with PT for UM have similar ocular outcomes and present the same metastasis incidence and OS as elder adults, their RS is worse than that in elder adults, when compared with the population in general.
- 26 April 2022
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 239 (04) , 586-589
Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib
Until recently, management of choroidal metastases (CM) was based on a set of fairly reliable assumptions. For example, the observation that in patients who present with CM and no relevant oncological history, a chest computed tomography (CT) scan will diagnose lung carcinoma as the primary tumor in a majority of cases. Or the fact that external beam radiation therapy (EBRT) is the standard treatment for CM and is often urgently indicated because of the secondary exudative retinal detachment and risk of blindness [1]. The impact of the COVID-19 pandemic on cancer care has been widely commented, mostly with regard to the discontinuation in screening programs, the risk of iatrogenic infection of patients and staff, and the delay in diagnostic, therapeutic, and follow-up procedures, as well as the suspension of clinical trials [2]. As far as we are aware, there are no specific examples with regard to the effect of COVID-19 on CM management. The arrival of systemic targeted therapies represents a more important and lasting game-changer, as they have improved life expectancy significantly in cancer patients who harbor the target mutation [1], [3], and specifically in lung cancer patients with EGFR (epidermal growth factor receptor) mutations [4], [5], [6]. However, for CM patients, this better prognosis implies that long-term radiation-induced side effects, in particular secondary ischemic retinopathy or optic neuropathy, become an increasing challenge. The use of targeted therapies as an alternative treatment for CM has been tried with first- and second-generation tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib, but met with resistance problems [3], [4], [5], [7], [8]. Osimertinib is a third-generation TKI that inhibits EGFR TKI as well as EGFR T790M resistance mutations, offering an alternative treatment in lung cancer patients. Its efficacy in the setting of CM has only been reported upon in one case [4]. Received: 26 September 2021 Accepted: 10 February 2022 Publication Date: 26 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 26 April 2022
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 239 (04) , 586-589
Delayed Diagnosis of Lung Carcinoma Presenting as Choroidal Metastasis in a COVID-19 Patient and Initially Treated with Osimertinib
Until recently, management of choroidal metastases (CM) was based on a set of fairly reliable assumptions. For example, the observation that in patients who present with CM and no relevant oncological history, a chest computed tomography (CT) scan will diagnose lung carcinoma as the primary tumor in a majority of cases. Or the fact that external beam radiation therapy (EBRT) is the standard treatment for CM and is often urgently indicated because of the secondary exudative retinal detachment and risk of blindness [1]. The impact of the COVID-19 pandemic on cancer care has been widely commented, mostly with regard to the discontinuation in screening programs, the risk of iatrogenic infection of patients and staff, and the delay in diagnostic, therapeutic, and follow-up procedures, as well as the suspension of clinical trials [2]. As far as we are aware, there are no specific examples with regard to the effect of COVID-19 on CM management. The arrival of systemic targeted therapies represents a more important and lasting game-changer, as they have improved life expectancy significantly in cancer patients who harbor the target mutation [1], [3], and specifically in lung cancer patients with EGFR (epidermal growth factor receptor) mutations [4], [5], [6]. However, for CM patients, this better prognosis implies that long-term radiation-induced side effects, in particular secondary ischemic retinopathy or optic neuropathy, become an increasing challenge. The use of targeted therapies as an alternative treatment for CM has been tried with first- and second-generation tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib, but met with resistance problems [3], [4], [5], [7], [8]. Osimertinib is a third-generation TKI that inhibits EGFR TKI as well as EGFR T790M resistance mutations, offering an alternative treatment in lung cancer patients. Its efficacy in the setting of CM has only been reported upon in one case [4]. Received: 26 September 2021 Accepted: 10 February 2022 Publication Date: 26 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 26 April 2022
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 239 (04) , 582-585
Bacillary Layer Detachment (BALAD) in Macular Choroidal Metastasis of a Low-grade Rectal Adenocarcinoma
Choroidal metastases are the most common intraocular malignant tumors in adults [1]. Because of its large vascular network, the choroid is the most frequently involved ocular layer. The majority of patients with choroidal metastasis have been previously diagnosed with systemic cancer. In one-third of the patients, the choroidal metastasis is found before the primary tumor [1]. Breast (45%) and lung cancer (25%) are the most common primary neoplasms [1]. The gastrointestinal tract (4%), in particular, the rectum (< 0.5%), is an unusual site of origin [1], [2]. Management of choroidal metastases is an emergency and requires close multidisciplinary teamwork, often involving radiation therapy, to avoid blindness and neovascular glaucoma because of total retinal detachment secondary to rapidly growing tumors. Multimodal imaging in the ophthalmic workup of these patients is essential, and optical coherence tomography enhanced depth imaging (OCT-EDI) has become an important tool in ocular oncology, especially in macular tumors. Bacillary layer detachment (BALAD) is a novel OCT terminology and is defined as a split at the level of the photoreceptor inner segment myoid, creating a distinct intraretinal cavity [3]. The photoreceptor inner segments are divided into two parts: the proximal myoid, near the external limiting membrane, and the distal ellipsoid zone (near the outer segment) [3]. The first OCT description of BALAD was made by Maruyama and Kishi [3] in a series of 21 patients with Vogt-Koyanagi-Harada (VKH) disease as “intraretinal fluid accumulation in the outer retina”. Rhamtohul et al. proposed a novel acronym “BALAD” (BAcillary LAyer Detachment) [3]. Received: 26 September 2021 Accepted: 17 February 2022 Publication Date: 26 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 26 April 2022
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 239 (04) , 582-585
Bacillary Layer Detachment (BALAD) in Macular Choroidal Metastasis of a Low-grade Rectal Adenocarcinoma
Choroidal metastases are the most common intraocular malignant tumors in adults [1]. Because of its large vascular network, the choroid is the most frequently involved ocular layer. The majority of patients with choroidal metastasis have been previously diagnosed with systemic cancer. In one-third of the patients, the choroidal metastasis is found before the primary tumor [1]. Breast (45%) and lung cancer (25%) are the most common primary neoplasms [1]. The gastrointestinal tract (4%), in particular, the rectum (< 0.5%), is an unusual site of origin [1], [2]. Management of choroidal metastases is an emergency and requires close multidisciplinary teamwork, often involving radiation therapy, to avoid blindness and neovascular glaucoma because of total retinal detachment secondary to rapidly growing tumors. Multimodal imaging in the ophthalmic workup of these patients is essential, and optical coherence tomography enhanced depth imaging (OCT-EDI) has become an important tool in ocular oncology, especially in macular tumors. Bacillary layer detachment (BALAD) is a novel OCT terminology and is defined as a split at the level of the photoreceptor inner segment myoid, creating a distinct intraretinal cavity [3]. The photoreceptor inner segments are divided into two parts: the proximal myoid, near the external limiting membrane, and the distal ellipsoid zone (near the outer segment) [3]. The first OCT description of BALAD was made by Maruyama and Kishi [3] in a series of 21 patients with Vogt-Koyanagi-Harada (VKH) disease as “intraretinal fluid accumulation in the outer retina”. Rhamtohul et al. proposed a novel acronym “BALAD” (BAcillary LAyer Detachment) [3]. Received: 26 September 2021 Accepted: 17 February 2022 Publication Date: 26 April 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 26 April 2022
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 239 (04) , 559-564
Valsalva-Induced Spontaneous Suprachoroidal Hemorrhage: A Case Report and Review of the Literature
We report a rare case of spontaneous suprachoroidal hemorrhage and present a systematic review of the literature using PubMed/Medline databases. Patients that developed a spontaneous suprachoroidal hemorrhage with a history of previous intraocular surgery were excluded. An 82-year-old male patient with no known ocular pathologies or surgical history was referred with acute ocular pain and decreased vision in the right eye (BCVA: 0.6 with hyperopic correction) following a Valsalva maneuver. General history included chronic heart failure and coronary artery disease, treated with anticoagulant and antihypertensive drugs. Dilated fundus examination revealed a posterior red-brown choroidal mass, with a thickness of 1.5 mm on B-scan ultrasonography. The lesion was not visible on fluorescein or indocyanine green angiography and was located under the choroid on B-scan optical coherence tomography. The diagnosis of a spontaneous suprachoroidal hemorrhage was evoked, and the patient was observed. Five months later, BCVA was 1.0 uncorrected, with a normal-appearing fundus. In a literature review, eight cases of spontaneous suprachoroidal hemorrhage following an episode of increased intrathoracic pressure were identified, including our patient. M/F ratio was 1 : 1, with a median age of 66.5 years. All cases presented systemic pathologies. All cases presented with a unilateral suprachoroidal hemorrhage. Only 2/8 patients had ocular comorbidities. Complications requiring treatment were noted in 4/8 cases, including 2 cases that resulted in the loss of the vision following an acute angle-closure glaucoma. Spontaneous resolution of the hemorrhage was observed in the other 4 patients. In 6/8 cases, vision recovered over a mean period of 10 weeks. In conclusion, spontaneous suprachoroidal hemorrhage following a Valsalva maneuver in eyes with no history of ocular surgery or trauma is rare, and has been associated with advanced age, cardiovascular disease and asthma. In severe cases (2/8) the eye was lost, while most cases (6/8) recovered, presenting a good visual outcome.
- 26 April 2022
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 239 (04) , 559-564
Valsalva-Induced Spontaneous Suprachoroidal Hemorrhage: A Case Report and Review of the Literature
We report a rare case of spontaneous suprachoroidal hemorrhage and present a systematic review of the literature using PubMed/Medline databases. Patients that developed a spontaneous suprachoroidal hemorrhage with a history of previous intraocular surgery were excluded. An 82-year-old male patient with no known ocular pathologies or surgical history was referred with acute ocular pain and decreased vision in the right eye (BCVA: 0.6 with hyperopic correction) following a Valsalva maneuver. General history included chronic heart failure and coronary artery disease, treated with anticoagulant and antihypertensive drugs. Dilated fundus examination revealed a posterior red-brown choroidal mass, with a thickness of 1.5 mm on B-scan ultrasonography. The lesion was not visible on fluorescein or indocyanine green angiography and was located under the choroid on B-scan optical coherence tomography. The diagnosis of a spontaneous suprachoroidal hemorrhage was evoked, and the patient was observed. Five months later, BCVA was 1.0 uncorrected, with a normal-appearing fundus. In a literature review, eight cases of spontaneous suprachoroidal hemorrhage following an episode of increased intrathoracic pressure were identified, including our patient. M/F ratio was 1 : 1, with a median age of 66.5 years. All cases presented systemic pathologies. All cases presented with a unilateral suprachoroidal hemorrhage. Only 2/8 patients had ocular comorbidities. Complications requiring treatment were noted in 4/8 cases, including 2 cases that resulted in the loss of the vision following an acute angle-closure glaucoma. Spontaneous resolution of the hemorrhage was observed in the other 4 patients. In 6/8 cases, vision recovered over a mean period of 10 weeks. In conclusion, spontaneous suprachoroidal hemorrhage following a Valsalva maneuver in eyes with no history of ocular surgery or trauma is rare, and has been associated with advanced age, cardiovascular disease and asthma. In severe cases (2/8) the eye was lost, while most cases (6/8) recovered, presenting a good visual outcome.
- Open Access
Clinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy
Objective: To assess oncological and ophthalmological outcomes after international referral of uveal melanoma patients for proton therapy. Materials and Methods: This is a retrospective study among Dutch uveal melanoma patients who were treated in Switzerland with 60.0 CGE proton therapy (in 4 fractions) from 1987 to 2019. All patients were ineligible for brachytherapy due to tumour size and/or proximity to the optic nerve. Time-to-event analyses were performed using Kaplan–Meier’s methodology and Cox proportional hazards models. Results: There were 103 patients (104 eyes) with a median largest tumour diameter of 19 mm (range 6–26 mm). Tumours were localised centrally (11%), mid-peripherally (65%) or peripherally (34%). Median follow-up was 7 years. Five-year local control, distant metastasis-free survival and eye preservation rates were 94%, 70% and 81% respectively. At five years, severe, moderate and mild visual impairment was observed in respectively 79%, 4% and 6% of the patients. Larger tumour volumes and more central tumour localisation were associated with severe visual impairment. After correction for these factors, dose to the macula, optic disc and retina, but not optic nerve was significantly associated with severe visual impairment. Conclusion: International referral for proton therapy yielded good tumour control and eye preservation rates, but risk of distant metastasis and severe visual impairment were substantial, possibly due to the selection of advanced tumour stages and/or central localisation. Dose to the macula may be more relevant than dose to the optic nerve for preservation of visual acuity, which is relevant for the treatment planning of proton therapy.
Open AccessClinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy
Objective: To assess oncological and ophthalmological outcomes after international referral of uveal melanoma patients for proton therapy. Materials and Methods: This is a retrospective study among Dutch uveal melanoma patients who were treated in Switzerland with 60.0 CGE proton therapy (in 4 fractions) from 1987 to 2019. All patients were ineligible for brachytherapy due to tumour size and/or proximity to the optic nerve. Time-to-event analyses were performed using Kaplan–Meier’s methodology and Cox proportional hazards models. Results: There were 103 patients (104 eyes) with a median largest tumour diameter of 19 mm (range 6–26 mm). Tumours were localised centrally (11%), mid-peripherally (65%) or peripherally (34%). Median follow-up was 7 years. Five-year local control, distant metastasis-free survival and eye preservation rates were 94%, 70% and 81% respectively. At five years, severe, moderate and mild visual impairment was observed in respectively 79%, 4% and 6% of the patients. Larger tumour volumes and more central tumour localisation were associated with severe visual impairment. After correction for these factors, dose to the macula, optic disc and retina, but not optic nerve was significantly associated with severe visual impairment. Conclusion: International referral for proton therapy yielded good tumour control and eye preservation rates, but risk of distant metastasis and severe visual impairment were substantial, possibly due to the selection of advanced tumour stages and/or central localisation. Dose to the macula may be more relevant than dose to the optic nerve for preservation of visual acuity, which is relevant for the treatment planning of proton therapy.
- Open Access
- 4 January 2021
- Published by Wolters Kluwer Health in Retina
- Vol. 41 (9) , 1883-1891
EIGHTEEN-MONTH RESULTS OF INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ON VISION AND MICROCIRCULATION IN RADIATION MACULOPATHY
Purpose: To evaluate 18 months' results of a strict anti–vascular endothelial growth factor protocol for radiation maculopathy following proton therapy in choroidal melanoma. Methods: Retrospective, comparative, nonrandomized study of 74 radiation maculopathy patients presenting macular lipid deposits, hemorrhages, microaneurysms, cystoid edema, nerve layer infarction, telangiectasia, or capillary nonperfusion. The study group included 52 consecutive patients injected with intravitreal anti–vascular endothelial growth factors (bevacizumab/ranibizumab: 46/6) every two months for the first and every 3 months for the second year, with minimum 12 months' follow-up. The control group consisted of 22 patients having declined this treatment. Best-corrected visual acuity, spectral domain-optical coherence tomography and optical coherence tomography angiography were recorded at baseline, 6, 12, and 18 months. The foveal avascular zone and capillary density were measured at the superficial capillary plexus. Results: Radiation maculopathy was diagnosed at 2 years (1.5–3.5) after proton therapy. Best-corrected visual acuity at baseline, 12 and 18 months improved in the study group from 0.45, 0.3 to 0.2 logarithm of the minimum angle of resolution, but decreased in the control group from 0.5, 0.9 to 1.0 logarithm of the minimum angle of resolution respectively (P < 0.001 at 12 months). Simultaneously, foveal avascular zone enlargement was less in the study (from 0.377, 0.665 to 0.744 mm2) than control group (from 0.436, 1.463 to 2.638 mm2) (P = 0.05 at 12 months). CMT (280 and 276 µm) and capillary density (37% and 38%, at baseline, respectively) did not evolve significantly different. Conclusion: Intravitreal anti–vascular endothelial growth factors, every 2 months for the first and every 3 months for the second year, slow down, over up to 18 months, vision loss and anatomical degradation in radiation maculopathy following proton therapy for choroidal melanoma.
- 4 January 2021
- Published by Wolters Kluwer Health in Retina
- Vol. 41 (9) , 1883-1891
Open AccessEIGHTEEN-MONTH RESULTS OF INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ON VISION AND MICROCIRCULATION IN RADIATION MACULOPATHY
Purpose: To evaluate 18 months' results of a strict anti–vascular endothelial growth factor protocol for radiation maculopathy following proton therapy in choroidal melanoma. Methods: Retrospective, comparative, nonrandomized study of 74 radiation maculopathy patients presenting macular lipid deposits, hemorrhages, microaneurysms, cystoid edema, nerve layer infarction, telangiectasia, or capillary nonperfusion. The study group included 52 consecutive patients injected with intravitreal anti–vascular endothelial growth factors (bevacizumab/ranibizumab: 46/6) every two months for the first and every 3 months for the second year, with minimum 12 months' follow-up. The control group consisted of 22 patients having declined this treatment. Best-corrected visual acuity, spectral domain-optical coherence tomography and optical coherence tomography angiography were recorded at baseline, 6, 12, and 18 months. The foveal avascular zone and capillary density were measured at the superficial capillary plexus. Results: Radiation maculopathy was diagnosed at 2 years (1.5–3.5) after proton therapy. Best-corrected visual acuity at baseline, 12 and 18 months improved in the study group from 0.45, 0.3 to 0.2 logarithm of the minimum angle of resolution, but decreased in the control group from 0.5, 0.9 to 1.0 logarithm of the minimum angle of resolution respectively (P < 0.001 at 12 months). Simultaneously, foveal avascular zone enlargement was less in the study (from 0.377, 0.665 to 0.744 mm2) than control group (from 0.436, 1.463 to 2.638 mm2) (P = 0.05 at 12 months). CMT (280 and 276 µm) and capillary density (37% and 38%, at baseline, respectively) did not evolve significantly different. Conclusion: Intravitreal anti–vascular endothelial growth factors, every 2 months for the first and every 3 months for the second year, slow down, over up to 18 months, vision loss and anatomical degradation in radiation maculopathy following proton therapy for choroidal melanoma.
- 18 April 2019
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 236 (04) , 422-424
Distant Subconjunctival Recurrences following Proton Therapy for a Choroidal Melanoma with Extrascleral Extension
Orbital recurrences after proton therapy for uveal melanoma are rare. They either occur in cases with an extrascleral extension at presentation [1], [2] or following transvitreal surgery or a transscleral biopsy [3], [4]. The former tends to be located outside the scleral wall facing the tumor scar and the latter at the site of scleral entry. We report our first case since 1984 of a double distant subconjunctival recurrence from a choroidal melanoma with an extrascleral extension at presentation, treated with proton therapy and without a biopsy procedure.
- 18 April 2019
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 236 (04) , 422-424
Distant Subconjunctival Recurrences following Proton Therapy for a Choroidal Melanoma with Extrascleral Extension
Orbital recurrences after proton therapy for uveal melanoma are rare. They either occur in cases with an extrascleral extension at presentation [1], [2] or following transvitreal surgery or a transscleral biopsy [3], [4]. The former tends to be located outside the scleral wall facing the tumor scar and the latter at the site of scleral entry. We report our first case since 1984 of a double distant subconjunctival recurrence from a choroidal melanoma with an extrascleral extension at presentation, treated with proton therapy and without a biopsy procedure.
- 28 March 2018
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 235 (04) , 473-475
Spontaneous Regression of Iris Melanocytoma: A Case Report
A melanocytoma is a rare, darkly pigmented nevus subtype, also called “magnocellular” nevus, as it consists of large and uniform polygonal cells with small nuclei and an intensely pigmented cytoplasm. It was first described by Zimmerman in 1962 at the level of the optic disc [1], and was subsequently identified within the iridociliary complex. The choroid, sclera, or conjunctiva are exceptional locations [2]. Iridociliary melanocytomas are benign tumors, whose evolution can be marked by slow and limited growth (23% after 5 years) [3], which can be difficult to differentiate clinically from malignant transformation (lifetime risk: 2 – 5%) [3], [4], [5]. Spontaneous necrosis with secondary pigment dispersion glaucoma is a frequent complication (11 – 30%) [2], [3], but to our knowledge, a nearly complete and spontaneous regression has never been reported.
- 28 March 2018
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 235 (04) , 473-475
Spontaneous Regression of Iris Melanocytoma: A Case Report
A melanocytoma is a rare, darkly pigmented nevus subtype, also called “magnocellular” nevus, as it consists of large and uniform polygonal cells with small nuclei and an intensely pigmented cytoplasm. It was first described by Zimmerman in 1962 at the level of the optic disc [1], and was subsequently identified within the iridociliary complex. The choroid, sclera, or conjunctiva are exceptional locations [2]. Iridociliary melanocytomas are benign tumors, whose evolution can be marked by slow and limited growth (23% after 5 years) [3], which can be difficult to differentiate clinically from malignant transformation (lifetime risk: 2 – 5%) [3], [4], [5]. Spontaneous necrosis with secondary pigment dispersion glaucoma is a frequent complication (11 – 30%) [2], [3], but to our knowledge, a nearly complete and spontaneous regression has never been reported.
- 12 March 2018
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 235 (04) , 453-455
Pseudometastatic Conjunctival Vegetative Foreign Bodies: A Case Report and Review of the Literature
Various pigmented foreign bodies can mimic a conjunctival melanoma. Case reports have documented both anorganic and organic substances as well as iatrogenic examples. To our knowledge, we present the first case of vegetal foreign bodies evoking possible metastases from a treated choroidal melanoma in the fellow eye.
- 12 March 2018
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 235 (04) , 453-455
Pseudometastatic Conjunctival Vegetative Foreign Bodies: A Case Report and Review of the Literature
Various pigmented foreign bodies can mimic a conjunctival melanoma. Case reports have documented both anorganic and organic substances as well as iatrogenic examples. To our knowledge, we present the first case of vegetal foreign bodies evoking possible metastases from a treated choroidal melanoma in the fellow eye.